Hepatitis C Milestone Tests NHS Funding for Rare Diseases

England is on track to become one of the first countries in the world to eliminate hepatitis C as a public health threat, according to NHS officials, but the achievement is fuelling a wider debate about how the health service should fund screening and treatment programmes for less prominent conditions once flagship targets are met. NHS England data show new hepatitis C diagnoses and treatment initiations have fallen sharply over the past decade, putting the country ahead of the World Health Organization's global elimination timeline.

A Milestone Years in the Making

Hepatitis C is a bloodborne virus that can cause serious liver damage, cirrhosis and liver cancer if left untreated. For decades it was considered a slow-moving but persistent public health problem, disproportionately affecting people who inject drugs, prison populations and those who received blood transfusions before rigorous screening began. The introduction of highly effective direct-acting antiviral drugs, combined with an aggressive NHS case-finding programme, has transformed the outlook.

According to NHS England, more than 80,000 people have been treated for hepatitis C since the elimination drive intensified, with cure rates exceeding 90% in most patient groups. Officials said sustained investment in outreach clinics, prison testing and needle-exchange partnerships has been central to driving down transmission.

How the Numbers Compare Globally

The World Health Organization has set a global target of eliminating viral hepatitis as a public health threat, defined as an 80% reduction in new infections and a 65% reduction in mortality. England is reporting progress well ahead of the average pace seen across comparable high-income countries, according to WHO surveillance data. The Lancet has previously published modelling suggesting that early and sustained investment in direct-acting antivirals produces long-term savings by reducing liver transplants, cancer treatment and end-stage liver disease admissions.

The Funding Question Behind the Success

The hepatitis C programme's success has prompted scrutiny of what comes next. With elimination targets in sight, some NHS commissioners are asking whether resources currently allocated to hepatitis C screening should be redirected toward other underfunded areas, including rare disease diagnostics and chronic disease monitoring. NICE has previously flagged that funding models built around single-disease elimination campaigns can struggle to adapt once prevalence falls, leaving specialist testing infrastructure underused or at risk of being dismantled prematurely.

Balancing Prevention Against New Priorities

Public health economists have warned that scaling back screening infrastructure too quickly could allow small pockets of undiagnosed infection to persist, undermining years of progress. A BMJ analysis of previous disease elimination campaigns found that maintaining a reduced but consistent testing capacity, rather than fully withdrawing funding, tends to be more cost-effective over a ten-year horizon than stopping and later restarting large-scale screening.

What This Means for Other NHS Priorities

The hepatitis C debate is unfolding against a backdrop of broader financial pressure across the health service. Just as the NHS has had to weigh competing demands in mental health provision and primary care, hepatitis officials must justify continued investment in a disease that is becoming rarer while other conditions compete for the same pool of funding. This tension echoes concerns raised in coverage of how the NHS faces fresh mental health funding crisis and how the NHS tackles record waiting lists with new GP funding, both of which illustrate how success in one clinical area often puts pressure on funding elsewhere.

Lessons From Cancer and Mental Health Funding Debates

Comparisons are increasingly being drawn with cancer services, where survival rates have improved despite persistent funding constraints, as detailed in reporting on NHS Cancer Survival Rates Rise Despite Funding Pressures. In both cancer and hepatitis care, officials have had to demonstrate that continued investment in diagnostics and monitoring remains cost-effective even as absolute case numbers fall. Similar arguments have been made in relation to the NHS faces new mental health funding crisis, where reduced acute demand in some areas has not translated into proportionate budget flexibility elsewhere.

Screening Strategy Going Forward

NHS England has indicated that future hepatitis C strategy will likely shift from mass case-finding toward targeted testing in high-risk groups, including people who inject drugs, migrants from countries with higher prevalence, and individuals with a history of blood transfusion before screening protocols were established. Officials said this recalibration is intended to preserve elimination gains while freeing up capacity for other diagnostic priorities.

Who Should Still Consider Testing

Public health guidance continues to recommend testing for specific groups, even as overall prevalence declines. The NHS and WHO both emphasise that many people with hepatitis C have no symptoms for years, making risk-based screening essential rather than reliance on symptom recognition alone.

• Anyone who has ever injected drugs, even once or many years ago
• People who received a blood transfusion or organ transplant before nineteen ninety-one in the UK
• Individuals who have had tattoos or piercings using unsterilised equipment
• People born in or with family from countries with higher hepatitis C prevalence
• Anyone who has shared razors, toothbrushes or other personal items with an infected person
• People experiencing unexplained fatigue, jaundice or abnormal liver function test results

What Comes After Elimination

Should England formally reach WHO elimination criteria, health officials say the focus will turn to maintaining low-level surveillance rather than eliminating testing infrastructure altogether. According to NHS England, this includes continued funding for prison health services, drug treatment centres and sexual health clinics, which have historically served as key entry points for diagnosis.

Implications for Rare Disease Funding Models

Some researchers argue the hepatitis C programme could serve as a template for other rare or declining-prevalence conditions, where sustained but reduced investment prevents resurgence. NICE has suggested that lessons from hepatitis funding allocation could inform how the NHS approaches other conditions nearing elimination thresholds, ensuring that success does not inadvertently lead to under-preparedness for future outbreaks.

As England approaches this milestone, the central challenge facing policymakers is not clinical but financial: how to preserve the infrastructure and expertise built over more than a decade of hepatitis C elimination work, without diverting resources that could address other pressing NHS priorities. Officials say decisions made over the coming budget cycles will determine whether this becomes a lasting public health success or a cautionary tale about the risks of declaring victory too soon.